中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01177 中国生物制药

已收盘 03-12 16:08:20

6.030

-0.070

-1.15%

最高6.160	最低5.930	成交量5,088万
今开6.110	昨收6.100	日振幅3.77%
总市值1,131亿	流通市值1,131亿	总股本187.61亿
成交额3.06亿	换手率0.27%	流通股本187.61亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01177","market":"HK","secType":"STK","nameCN":"中国生物制药","latestPrice":6.03,"timestamp":1773302900004,"preClose":6.1,"halted":0,"volume":50876125,"delay":0,"changeRate":-0.011475409836065476,"floatShares":18761000000,"shares":18761000000,"eps":0.191315,"marketStatus":"已收盘","change":-0.07,"latestTime":"03-12 16:08:20","open":6.11,"high":6.16,"low":5.93,"amount":306259887,"amplitude":0.037705,"askPrice":6.05,"askSize":126000,"bidPrice":6.03,"bidSize":605000,"shortable":3,"etf":0,"ttmEps":0.234308,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1773365400000},"marketStatusCode":5,"adr":0,"listingDate":1070812800000,"exchange":"SEHK","adjPreClose":6.1,"dividendRate":0.015525,"openAndCloseTimeList":[[1773279000000,1773288000000],[1773291600000,1773302400000]],"volumeRatio":0.63569,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"SBO.HK","impliedVol":0.2593,"impliedVolPercentile":0.0447},"requestUrl":"/m/hq/s/01177","defaultTab":"news","newsList":[{"id":"1181896301","title":"中国生物制药TQB3454 IDH1抑制剂针对胆道癌III期临床试验获积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1181896301","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181896301?lang=zh_cn&edition=full","pubTime":"2026-03-12 17:08","pubTimestamp":1773306516,"startTime":"0","endTime":"0","summary":"中国生物制药宣布，其研发的TQB3454 IDH1抑制剂在针对胆道癌的III期临床试验中取得积极成果。该研究达到主要终点，显示药物可显著延长患者无进展生存期，且安全性与耐受性良好。\n此次突破为胆道癌患者提供了新的治疗选择，标志着公司在创新药研发领域的重要进展。TQB3454作为口服靶向药物，通过抑制IDH1突变蛋白活性发挥抗肿瘤作用。\n公司计划基于该数据向国家药品监督管理局提交上市申请，若获批将成为国内首个针对胆道癌的IDH1抑制剂。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","BK1521","01177","HK0000165453.HKD","IE00BZ08YS42.EUR","BK1515","BK1589"],"gpt_icon":0},{"id":"1123643643","title":"中国生物制药TQB3205泛KRAS抑制剂获NMPA批准开展晚期恶性肿瘤临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1123643643","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123643643?lang=zh_cn&edition=full","pubTime":"2026-03-11 19:05","pubTimestamp":1773227114,"startTime":"0","endTime":"0","summary":"中国生物制药宣布，其自主研发的TQB3205泛KRAS抑制剂已获得国家药品监督管理局（NMPA）批准，将针对晚期恶性肿瘤开展临床试验。该药物作为创新靶向治疗产品，有望为相关癌症患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1515","HK0000165453.HKD","IE00BZ08YT58.USD","BK1521","IE00BZ08YS42.EUR","BK1589","IE00BZ08YR35.GBP","01177"],"gpt_icon":0},{"id":"2618491779","title":"中国生物制药(01177)：TQB3205(pan-KRAS 抑制剂)临床试验获NMPA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2618491779","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618491779?lang=zh_cn&edition=full","pubTime":"2026-03-11 19:04","pubTimestamp":1773227096,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 发布公告，本集团附属公司正大天晴药业集团股份有限公司自主研发的国家1类创新药TQB3205已获得中国国家药品监督管理局的临床试验批准，拟用于治疗晚期恶性肿瘤。TQB3205是一款口服的pan-KRAS抑制剂。目前全球已获批上市的5款KRAS抑制剂均仅针对G12C单一突变亚型。本集团联合开发的KRAS G12C抑制剂格索雷塞已于2024年11月获得NMPA的上市批准。尽管如此，KRAS领域的临床需求远未得到满足，亟需能覆盖更广泛突变亚型的pan-KRAS抑制剂。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412732.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BZ08YS42.EUR","BK1589","HK0000165453.HKD","IE00BZ08YR35.GBP","BK1515","IE00BZ08YT58.USD","BK1191","BK1521","01177"],"gpt_icon":0},{"id":"2618925435","title":"医药生物行业周报：罗伐昔替尼达成高额独家授权协议，创新药BD交易持续活跃","url":"https://stock-news.laohu8.com/highlight/detail?id=2618925435","media":"上海证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618925435?lang=zh_cn&edition=full","pubTime":"2026-03-11 14:05","pubTimestamp":1773209138,"startTime":"0","endTime":"0","summary":"主要观点2026年3月4日，中国生物制药宣布与赛诺菲就罗伐昔替尼达成独家授权协议。根据协议，中国生物制药子公司正大天晴授予赛诺菲在全球范围内开发、生产及商业化罗伐昔替尼的独家许可。四起交易均为临床前资产，彰显中国源头创新能力获全球认可。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031114054897ad2986&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031114054897ad2986&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BZ08YT58.USD","LU1993786604.SGD","IE00BZ08YR35.GBP","IE0008369823.USD","01093","BK1574","LU1951186391.HKD","LU1226287792.SGD","IE00B543WZ88.USD","BK1191","HK0000165453.HKD","LU0140636845.USD","IE0008368742.USD","LU1226288170.HKD","LU2039709279.SGD","IE00B031HY20.USD","LU0315179316.USD","BK1515","01177","LU0072913022.USD","LU0501845795.SGD","LU0326950275.SGD","IE00BZ08YS42.EUR","LU1328277881.USD","LU1226287875.USD","LU1807302812.USD","SG9999004220.SGD","IE00B5MMRT66.SGD","LU1008478684.HKD","LU1813983027.USD","LU1152091168.USD","LU1226288253.USD","LU0067412154.USD","06978","BK1521","LU0314109678.HKD","01801","LU0880133367.SGD","LU1960683339.HKD","LU1152091754.HKD","LU1226287529.USD","BK1161"],"gpt_icon":0},{"id":"2618095226","title":"每日卖空追踪 | 中国生物制药 03月10日卖空量成交843.5万股，卖空比例为10.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618095226","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618095226?lang=zh_cn&edition=full","pubTime":"2026-03-10 16:30","pubTimestamp":1773131419,"startTime":"0","endTime":"0","summary":"中国生物制药北京时间03月10日，涨0.16%，卖空量成交843.5万股，较上一交易日减少72.89%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310163209a45df65a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310163209a45df65a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BZ08YR35.GBP","IE00BZ08YT58.USD","01177","HK0000165453.HKD","BK1521","BK1589","BK1515","BK1191","IE00BZ08YS42.EUR"],"gpt_icon":0},{"id":"2618952245","title":"中国生物制药03月10日主力净流入4113.1万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2618952245","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618952245?lang=zh_cn&edition=full","pubTime":"2026-03-10 16:15","pubTimestamp":1773130538,"startTime":"0","endTime":"0","summary":"03月10日, 中国生物制药股价涨0.16%，报收6.18元，成交金额4.8亿元，换手率0.41%，振幅2.92%，量比0.82。中国生物制药今日主力资金净流入4113.1万元，上一交易日主力净流出9233.8万元。该股近5个交易日上涨9.28%，主力资金累计净流出1115.6万元；近20日主力资金累计净流入9220.0万元，其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310161748a45de893&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310161748a45de893&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","HK0000165453.HKD","BK1515","01177","IE00BZ08YS42.EUR","BK1589","IE00BZ08YT58.USD","BK1521","IE00BZ08YR35.GBP"],"gpt_icon":0},{"id":"2617660738","title":"医药生物行业周报：制药行业 继续看好国际化、政策支持和技术突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2617660738","media":"中信建投证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617660738?lang=zh_cn&edition=full","pubTime":"2026-03-08 00:00","pubTimestamp":1772899200,"startTime":"0","endTime":"0","summary":"核心观点：2020年以来，中国创新药国际化从产品输出迈向战略与组织协同。政策端，医保谈判效率提升且降幅趋稳，叠加2025年首次设立的商保目录，创新药放量空间扩大。基于国际化竞争力、技术突破与政策红利，看好具备自主出海能力的龙头、深耕前沿赛道的平台型公司，以及能通过真创新保持利润增长的企业。创新药及制药企业、器械。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260308164207a6aeb259&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260308164207a6aeb259&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","HK0000165453.HKD","IE00BZ08YR35.GBP","BK1515","IE00BZ08YS42.EUR","01177","IE00BZ08YT58.USD","01477","BK1191","BK1589","BK1521"],"gpt_icon":0},{"id":"2617638749","title":"一周医药速览（02.02-02.06）","url":"https://stock-news.laohu8.com/highlight/detail?id=2617638749","media":"财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617638749?lang=zh_cn&edition=full","pubTime":"2026-03-06 15:45","pubTimestamp":1772783158,"startTime":"0","endTime":"0","summary":"京东健康：2025年净利润增长29.1%至53.75亿元，全年新药首发超100款近日，京东健康发布截至2025年12月31日止年度的年度业绩公告。截至2025年底，公司自营药房门店已超过300家。德琪医药将获得8000万美元的首付款及近期里程碑付款，其中包括6000万美元的首付款和满足若干条件后额外支付的2000万美元里程碑付款。公告显示，整体收入为5.49亿美元，较2024年下降13%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306155002a4532b1f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306155002a4532b1f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01177","BK1583","BK1515","BK1161","06996","09939","BK1574","BK1191"],"gpt_icon":0},{"id":"2617506588","title":"中国生物制药盘中异动 股价大涨3.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617506588","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617506588?lang=zh_cn&edition=full","pubTime":"2026-03-06 09:59","pubTimestamp":1772762356,"startTime":"0","endTime":"0","summary":"2026年03月06日早盘09时59分，中国生物制药股票出现波动，股价急速拉升3.05%。截至发稿，该股报6.090港元/股，成交量1338万股，换手率0.07%，振幅3.05%。中国生物制药股票所在的药品行业中，整体涨幅为1.26%。其相关个股中，和黄医药、三生制药、信达生物涨幅较大，振幅较大的相关个股有三生制药、和黄医药、宝济药业-B，振幅分别为9.63%、9.50%、8.13%。中国生物制药公司简介：本集团业务覆盖医药各种研发平台、智能化生产和强大销售体系全产业链。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030609591697a847dc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"e7c1b3f05d683fbcbbd58e2898b18438","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030609591697a847dc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01177","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","HK0000165453.HKD","IE00BZ08YS42.EUR","BK1515","BK1191","BK1589","BK1521"],"gpt_icon":0},{"id":"2617504034","title":"15亿美元再添捷报！2026国产创新药出海热潮仍在持续","url":"https://stock-news.laohu8.com/highlight/detail?id=2617504034","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617504034?lang=zh_cn&edition=full","pubTime":"2026-03-06 09:42","pubTimestamp":1772761338,"startTime":"0","endTime":"0","summary":"春节过后，国产创新药出海热潮丝毫不减，持续书写着中国医药创新的全球化新篇章。进入3月份，创新药出海又传来捷报，中国生物制药宣布达成15.3 亿美金创新药授权交易。据悉，2026年开年至今，中国药企出海节奏密集。如信达生物与礼来制药再次达成战略合作，合作金额最高达88.5亿美元，双方将在肿瘤和免疫疾病领域联合开发全新药物。协议未披露涉及的具体药物数量。展望2026年，国产创新药出海将呈现出全新格局。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306094344a451ed8b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306094344a451ed8b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1589","BK1521","HK0000165453.HKD","IE00BZ08YT58.USD","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","01801","BK1515","BK1574","01177","BK1161","BK1191","06978"],"gpt_icon":0},{"id":"2617506308","title":"每日卖空追踪 | 中国生物制药 03月05日卖空量成交2093.6万股，卖空比例为19.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617506308","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617506308?lang=zh_cn&edition=full","pubTime":"2026-03-05 16:30","pubTimestamp":1772699420,"startTime":"0","endTime":"0","summary":"中国生物制药北京时间03月05日，涨3.5%，卖空量成交2093.6万股，较上一交易日减少35.54%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305163219a6a5d704&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305163219a6a5d704&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01177","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","HK0000165453.HKD","IE00BZ08YS42.EUR","BK1515","BK1191","BK1589","BK1521"],"gpt_icon":0},{"id":"2617596171","title":"反弹来了！港股通创新药ETF（520880）大涨超3%！中国生物制药新签大单，创移植赛道最大规模交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2617596171","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617596171?lang=zh_cn&edition=full","pubTime":"2026-03-05 10:14","pubTimestamp":1772676840,"startTime":"0","endTime":"0","summary":"创新药龙头普涨，100%创新药研发标的——港股通创新药ETF高开高走，现涨超3%。昨日，520880录得五连跌，场内价格创下历史新低，不过资金逆行增仓，连续5日低吸合计逾1.35亿元。　　权重股中国生物制药大涨超5%，该股昨日公告称，与赛诺菲就罗伐昔替尼订立独家授权协议，获1.35亿美元首付款、最高13.95亿美元里程碑付款，并享有基于年度净销售额的最高双位数阶梯式特许权使用费。这是中国药企在移植领域创下的最大规模对外授权交易。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-03-05/doc-inhpwzrx3294783.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1589","IE00BZ08YT58.USD","BK1191","BK1515","HK0000165453.HKD","01177","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP","520880","BK1521"],"gpt_icon":0},{"id":"2617659546","title":"港股异动 | 中国生物制药(01177)涨超5% 罗伐昔替尼授权赛诺菲 潜在收款超15亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2617659546","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617659546?lang=zh_cn&edition=full","pubTime":"2026-03-05 10:06","pubTimestamp":1772676375,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中国生物制药涨超5%，暂领升蓝筹。根据协议，中国生物制药子公司正大天晴授予赛诺菲在全球范围内开发、生产及商业化罗伐昔替尼的独家许可。中国生物制药有权获得最高15.3亿美元的付款，其中包括1.35亿美元的首付款以及潜在开发、监管及销售里程碑付款，另外还将获得基于罗伐昔替尼年度净销售额的最高双位数的阶梯式特许权使用费。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1410283.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BZ08YR35.GBP","BK4585","BK1589","HK0000165453.HKD","IE00BZ08YS42.EUR","VXUS","BK1521","BK1515","IE00BZ08YT58.USD","BK1191","BK4588","01177","VT"],"gpt_icon":0},{"id":"1190696923","title":"异动解读 | 中国生物制药与赛诺菲达成重磅授权协议，股价盘中大涨5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=1190696923","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190696923?lang=zh_cn&edition=full","pubTime":"2026-03-05 10:04","pubTimestamp":1772676284,"startTime":"0","endTime":"0","summary":"中国生物制药（01177）今日盘中股价大幅上涨5.08%，引起了市场的广泛关注。消息面上，公司宣布其附属公司正大天晴与赛诺菲就全球首创口服小分子JAK/ROCK双靶点抑制剂罗伐昔替尼（商品名：安煦）订立了独家授权协议。根据协议，中国生物制药将获得1.35亿美元的首付款、最高可达13.95亿美元的里程碑付款，并享有基于该药物年度净销售额的最高双位数阶梯式特许权使用费。此次授权标志着中国生物制药在创新药全球化布局上取得重大突破，市场预期该交易将显著增厚公司未来多年的收入与利润，并强化其在血液肿瘤及免疫纤维化领域的国际竞争力，从而推动了股价的积极表现。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01177"],"gpt_icon":0},{"id":"2617938555","title":"3月起，中药将面临最严监管；中国生物制药与赛诺菲订立授权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2617938555","media":"21世纪经济报道","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617938555?lang=zh_cn&edition=full","pubTime":"2026-03-05 08:08","pubTimestamp":1772669305,"startTime":"0","endTime":"0","summary":"政策动向市场监管总局进一步加强特殊医学用途配方食品安全监管市场监管总局近日修订发布《特殊医学用途配方食品生产许可审查细则（2026版）》。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603053662416791.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603053662416791.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE00BZ08YR35.GBP","HK0000165453.HKD","BK1515","01177","IE00BZ08YT58.USD","BK1589","BK1191","IE00BZ08YS42.EUR","BK1521"],"gpt_icon":0},{"id":"2617560656","title":"每日卖空追踪 | 中国生物制药 03月04日卖空量成交1178.9万股，卖空比例为13.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617560656","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617560656?lang=zh_cn&edition=full","pubTime":"2026-03-04 16:30","pubTimestamp":1772613019,"startTime":"0","endTime":"0","summary":"中国生物制药北京时间03月04日，股价较前一交易日持平，卖空量成交1178.9万股，较上一交易日减少62.12%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304163222a44a6b30&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304163222a44a6b30&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BZ08YS42.EUR","IE00BZ08YT58.USD","BK1521","BK1191","HK0000165453.HKD","IE00BZ08YR35.GBP","01177","BK1515","BK1589"],"gpt_icon":0},{"id":"2617560570","title":"中国生物制药03月04日获主力加仓116.7万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2617560570","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617560570?lang=zh_cn&edition=full","pubTime":"2026-03-04 16:15","pubTimestamp":1772612128,"startTime":"0","endTime":"0","summary":"03月04日，中国生物制药股价收平报5.71元，成交金额5.1亿元，换手率0.48%，振幅4.55%，量比1.10。中国生物制药今日主力资金净流入116.7万元，连续4日净流入，上一交易日主力净流入1557.7万元。近一年数据显示，该股主力连续4日净流入后，次日上涨概率为41.67%，平均涨幅为2.87%。该股近5个交易日下跌10.17%，主力资金累计净流入5970.5万元；近20日主力资金累计净流入1.2亿元，其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304161643a6a13b03&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304161643a6a13b03&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1589","01177","IE00BZ08YR35.GBP","BK1191","IE00BZ08YS42.EUR","IE00BZ08YT58.USD","BK1521","HK0000165453.HKD"],"gpt_icon":0},{"id":"2616774663","title":"中国生物制药(01177)与Sanofi就罗伐昔替尼订立独家授权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2616774663","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616774663?lang=zh_cn&edition=full","pubTime":"2026-03-04 06:19","pubTimestamp":1772576365,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 公布，集团附属公司正大天晴药业集团股份有限公司已与Sanofi S.A.的一间全资附属公司就集团的JAK/ROCK抑制剂罗伐昔替尼在全球的开发、生产及商业化订立独家授权协议。根据协议条款，该集团将授予Sanofi在全球范围内开发、生产及商业化罗伐昔替尼的独家许可。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1409708.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","01177","SNYNF","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","GCVRZ","HK0000165453.HKD","IE00BZ08YS42.EUR","BK1515","BK1191","BK1589","BK1521"],"gpt_icon":0},{"id":"2616113874","title":"中国生物制药(01177)自主研发的国家1类创新药罗伐昔替尼片获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2616113874","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616113874?lang=zh_cn&edition=full","pubTime":"2026-03-02 06:19","pubTimestamp":1772403584,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 公布，该集团自主研发的国家1类创新药罗伐昔替尼片已获得中国国家药品监督管理局的上市批准，用于中危-2或高危的原发性骨髓纤维化、真性红细胞增多症后骨髓纤维化 或原发性血小板增多症后骨髓纤维化成年患者的一线治疗。安全性方面，罗伐昔替尼总体耐受性良好，相关研究中≥3级不良反应发生率约40%，贫血发生率约40%，治疗终止率仅 6.7%，均远低于芦可替尼。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1408712.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","IE00BZ08YT58.USD","HK0000165453.HKD","BK1161","BK1589","IE00BZ08YS42.EUR","159992","BK1515","BK1521","BK1574","IE00BZ08YR35.GBP","01177","06978"],"gpt_icon":0},{"id":"2614907311","title":"中国生物制药盘中异动 下午盘急速下跌3.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614907311","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614907311?lang=zh_cn&edition=full","pubTime":"2026-02-26 15:26","pubTimestamp":1772090797,"startTime":"0","endTime":"0","summary":"2026年02月26日下午盘15时26分，中国生物制药股票出现波动，股价大幅跳水3.29%。截至发稿，该股报6.180港元/股，成交量5457.18万股，换手率0.29%，振幅3.91%。中国生物制药股票所在的药品行业中，整体跌幅为1.18%。其相关个股中，精优药业、泰德医药、中国医疗集团涨幅较大，振幅较大的相关个股有宝济药业-B、德琪医药-B、精优药业，振幅分别为17.11%、12.09%、12.05%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226152637a7214f60&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226152637a7214f60&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","BK1589","01177","IE00BZ08YT58.USD","BK1515","BK1521","HK0000165453.HKD","BK1191"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sinobiopharm.com","stockEarnings":[{"period":"1week","weight":0.0683},{"period":"1month","weight":-0.0758},{"period":"3month","weight":-0.0936},{"period":"6month","weight":-0.2932},{"period":"1year","weight":0.7374},{"period":"ytd","weight":-0.0129}],"compareEarnings":[{"period":"1week","weight":0.0257},{"period":"1month","weight":-0.0418},{"period":"3month","weight":0.0144},{"period":"6month","weight":-0.0185},{"period":"1year","weight":0.089},{"period":"ytd","weight":0.0105}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"中国生物制药有限公司是一家主要从事制药业务的投资控股公司。该公司通过三个分部运营。中药现代制剂及西药分部主要从事生产、销售及配销中药现代制剂及西药产品业务。投资分部主要从事长期投资业务。其他分部主要从事相关医疗及医院业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.434783,"avgChangeRate":0.008254},{"month":2,"riseRate":0.652174,"avgChangeRate":0.056687},{"month":3,"riseRate":0.608696,"avgChangeRate":0.046515},{"month":4,"riseRate":0.5,"avgChangeRate":0.025891},{"month":5,"riseRate":0.727273,"avgChangeRate":0.043347},{"month":6,"riseRate":0.363636,"avgChangeRate":0.00957},{"month":7,"riseRate":0.636364,"avgChangeRate":0.047691},{"month":8,"riseRate":0.409091,"avgChangeRate":-0.010062},{"month":9,"riseRate":0.409091,"avgChangeRate":-0.015174},{"month":10,"riseRate":0.545455,"avgChangeRate":0.025184},{"month":11,"riseRate":0.5,"avgChangeRate":0.066781},{"month":12,"riseRate":0.409091,"avgChangeRate":-0.01175}],"exchange":"SEHK","name":"中国生物制药","nameEN":"SINO BIOPHARM"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供中国生物制药(01177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"中国生物制药,01177,中国生物制药股票,中国生物制药股票老虎,中国生物制药股票老虎国际,中国生物制药行情,中国生物制药股票行情,中国生物制药股价,中国生物制药股市,中国生物制药股票价格,中国生物制药股票交易,中国生物制药股票购买,中国生物制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供中国生物制药(01177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}